Table 3.

Meta-analysis of RFC1 G80A polymorphism and hematological malignance

Variables	A vs. G			AA vs. GG			GA vs. GG			AA+GA vs. GG			AA vs. AG+GG
	OR	95%CI	P	OR	95%CI	P	OR	95%CI	P	OR	95%CI	P	OR	95%CI	P
Overall	1.11	1.00-1.23	0.045	1.21	0.99-1.47	0.063	1.18	1.06-1.31	0.002	1.18	1.07-1.29	0.001	1.07	0.90-1.27	0.439
Ethnicity
Caucasian	1.12	0.99-1.26	0.070	1.24	0.97-1.58	0.092	1.28	1.12-1.45	<0.001	1.21	1.08-1.36	0.001	1.09	0.86-1.38	0.493
Asian	1.10	0.90-1.34	0.372	1.17	0.80-1.71	0.424	1.01	0.84-1.22	0.898	1.11	0.94-1.31	0.212	1.05	0.82-1.34	0.696
Cancer type
ALL	1.15	0.99-1.34	0.069	1.29	0.96-1.79	0.095	1.13	1.00-1.28	0.048	1.28	1.13-1.46	<0.001	1.09	0.84-1.40	0.537
NHL	1.06	0.96-1.17	0.245	1.13	0.93-1.38	0.228	1.16	0.88-1.52	0.285	1.06	0.92-1.23	0.425	1.10	0.93-1.31	0.266
PCNSL	0.89	0.67-1.18	0.398	0.75	0.42-1.31	0.308	1.34	0.94-1.91	0.102	0.96	0.64-1.45	0.851	0.72	0.43-1.20	0.204
AML	1.71	0.89-3.30	0.109	2.68	0.73-9.90	0.139	2.57	1.37-4.85	0.003	2.37	0.75-7.43	0.140	1.64	0.61-4.42	0.327

ALL, acute lymphoblast leukemia; NHL, Non- Hodgkin leukemia; PCNSL, primary central nervous system lymphoma; AML, acute myeloid leukemia